Фармакогенетические аспекты тяжелой астмы

1. Global Initiative for Asthma. Workshop report [Электронный ресурс], 2006. Доступ: http://www.ginasthma.com/download.asp?intId=217

2. Wechsler M.E., Elliot I. How pharmacogenomis will play a role in the management of asthma. Am. J. Respir. Crit. Care Med 2005; 172: 12–18.

3. Мазуров В.И., Шавловский М.М. Диагностическое и прогностическое значение эндогенных факторов риска. Мед. акад. журн. 2006; 6 (1): 73–83.

4. Середенин С.Б. Лекции по фармакогенетике. М.: Медицинское информационное агентство; 2004.

5. Rosenwasser L., Klemn J.D., Klemn J.M. et al. Association of asthmatic steroid intensivity with an IL-4 gene promoter polymorphism. J. Allergy Clin. Immunol 2001; 107: 235.

6. Freidin M.V., Kobyakova O.S., Ogorodova L.M. et al. Association of polymorphisms in the human IL4 and IL5 genes with atopic bronchial asthma and severity of the disease. Comparative Func. Genom. 2003; 4: 346–350.

7. Graves P.E. A claster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J. Allergy Clin. Immunol. 2000; 105 (3): 506–513.

8. Saito A. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int. Arch. Allergy Immunol. 2003; 132 (2): 168–176.

9. Ito K., Chung K.F., Adcock I.M. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 2006; 117 (3): 522–543.

10. Holgate S.T., Davies D.E., Powell R.M. et al. Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms. Eur. Respir. J. 2007; 29: 793–803.

11. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. J. Annual. Rev. Genomics Hum. Genet. 2001; 2: 9–39.

12. Palmer L.J., Silberman E.S., Weiss S.T. et al. Pharmacogenetics of asthma. Am. J. Respir. Crit. Care Med. 2000; 165 (7): 861–866.

13. Scott M.G., Swan C., Wheatley A.P. et al. Identification of novel polymorphisms within the promoter region of the human β2 -adrenergic receptor gene. Br. J. Pharmacol. 1999; 126: 841–844.

14. Thakkinstian A., McEvoy M., Minelli C. et al. Systematic review and meta-analysis of the association between β2 -adrenoreceptor polymorphisms and asthma. Am. J. Epidemiol. 2005; 162: 201–211.

15. Lima J.J., Thomason D.B., Mohamed M.H. et al. Impact of genetic polymorphisms of the β2 -adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. 1999; 65: 519–525.

16. Martinez F.D., Graves P.E., Baldini M. et al. Association between genetic polymorphisms of the β2 -adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 1997; 100: 3184–3188.

17. Drysdale C., McGraw D.W., Stack C. et al. Complex promoter and coding region β2 -adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Nat. Acad. Sci. USA 2000; 97: 10483–10488.

18. Zhang G., Hayden C.M., Khoo S K. et al. β2 -adrenoreceptor polymorphisms and asthma phenotypes: interactions with passive smoking. Eur. Respir. J. 2007; 30: 48–55.

19. Drazen J.M., Yandava C.N., Dube L. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 1999; 22: 168–170.

20. Silverman E.S., Drazen J.M. Genetic variations in the 5-lipoxygenase core promoter. Am. J. Respir. Crit. Care Med. 2000; 161: 77–80.

21. Bray P.J. Cotton R.G.H. Variations of the human glucocorticoid receptor gene NR3C1: Pathological and in vitro mutations and polymorphisms. J. Human. Mutation 2003; 21 (6): 557–568.

22. Huizenga N.A., Koper J.W., De Lange P. et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 1998; 83: 144–151.

23. Hawkins G.A., Amelung P.J., Richard S. et al. Identification of Polymorphisms in the Human Glucocorticoid Receptor Gene (NR3C1) in a Multi-racial Asthma Case and Control Screening Panel. J. DNA Seq. 2004; 15 (3): 167–173.

24. Kunz S., Sandoval R. Identification of a Novel Glucocorticoid Receptor Mutation in Budesonide-Resistant Human Bronchial Epithelial Cells. J. Mol. Endocrinol. 2003; 17 (12): 2566–2582.

25. Papi A. Investigating the steroids and longacting beta2agonists combination: why do we need more? Eur. Respir. J. 2004; 23: 501–502.

26. Tantisira K.G., Lake S., Silverman E.S. et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 2004; 13: 1353–1359.

27. Silverman E.S., Breault D.T., Vallone J. et al. Corticotropinreleasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. J. Allergy Clin. Immunol. 2004; 114: 747–754.

28. Hall I.P. Pharmacogenetics, pharmacogenomica and airway disease. J. Respir. Res. 2002; 13 (1): 10.

29. Okamoto K., Tanaka H., Ogawa H. et al. Redoxdependent regulation of nuclear import of the glucocorticoid receptor. J. Biol. Chen. 1999; 274: 10363–10371.

30. Baraldi E., Ghiro L., Piovan V.,Carraro S. et al. Increased exhaled 8-isoprostan in childhood asthma. Chest 2003; 124: 25–31.

31. Rangasamy T., Guo J., Mitzner W.A. et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 2005; 202: 47–59.

32. Баранов В.С., Баранова Е.В., Иващенко Т.Э., Асеев М.В. Геном человека и гены "предрасположенности": Введение в предективную медицину. СПб: Интермедика; 2000.

33. Evans W.E., McLeod H.L. Pharmacogenomics – drug desposition, drug targ effects. N. Engl. Med. 2003; 348 (6): 371–375.

34. Farrell R.J., Kelleher D.В. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrin. 2003; 178: 339–346.